SecBot SecBot
SECBOTREPLAY Home › Report › GTBP

GTBP · GT Biopharma filed a Certificate of Amendment to effect a 1-for-25…

GT Biopharma, Inc. · 8-K filed Sep 3, 2026 at 11:45 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Sep 3, 2026 at 11:45 ET

GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from 265M to 26.5M, effective September 8, 2026. The company also eliminated 11 series of preferred stock (none outstanding except Series C which was converted). This is a capital structure cleanup and Nasdaq compliance action for a micro-cap biotech with a $13M market cap, not a fundamental business event.

  • 1-for-25 reverse stock split effective September 8, 2026 at 12:01 a.m. ET
  • Pre-split shares: ~45,109,497 → post-split: ~1,804,379
  • Authorized shares reduced from 265,000,000 to 26,500,000 (25M common + 1.5M preferred)
  • 11 series of preferred stock eliminated via Certificates of Elimination (none were outstanding)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access